Please login to the form below

Not currently logged in
Email:
Password:

Relay Therapeutics appoints Sarah O’Brien as VP of HR

She joins the biotech from Sobi

Sarah O'BrienRelay Therapeutics, a biotech based in the US, has appointed its new vice president of human resources in the form of Sarah O’Brien.

She joins the biotech from Sobi in North America, where she was responsible for a variety of global initiatives across learning, development and culture.

O’Brien said: “I am thrilled to join this exceptional team that has a strong culture and compelling scientific approach.

“I am passionate about supporting growth and development at Relay so that we can create medicines wit meaningful clinical impact.”

Prior to Sobi, O’Brien spent seven years working at Novartis for its vaccines arm and then with the Novartis Institute for Biomedical Research (NIBR), where she worked closely with the translational medicines, oncology and immunotherapy organisations.

Sanjiv Patel, president and chief executive officer, Relay Therapeutics, said: “Sarah brings with her valuable insights that can be applied to continue advancing our commitment to advancing drug discovery and developing our team.

“We look forward to her working across the organisation to guide Relay’s growth while ensuring that we retain our strong commitment to both our people and culture, and remain true to our core values.”

5th December 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics